Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 Mar;63(2):126-139.
doi: 10.4111/icu.20210361.

Tumor enucleation for the treatment of T1 renal tumors: A systematic review and meta-analysis

Affiliations
Meta-Analysis

Tumor enucleation for the treatment of T1 renal tumors: A systematic review and meta-analysis

Hyun Chul Chung et al. Investig Clin Urol. 2022 Mar.

Abstract

Purpose: To evaluate the clinical efficacy and safety of tumor enucleation (TE) compared with partial nephrectomy (PN) for T1 renal cell carcinoma.

Materials and methods: According to protocol, we searched multiple data sources for published and unpublished randomized controlled trials and nonrandomized studies (NRSs) in any language. We performed systematic review and meta-analysis according to the Cochrane Handbook for Systematic Reviews of Interventions and rated the certainty of the evidence (CoE) using the GRADE framework.

Results: We are uncertain about the effects of TE on perioperative (mean difference [MD] 3.38, 95% CI 1.52 to 5.23; I²=68%; 4 NRSs; 942 participants; very low CoE) and long-term (MD 2.31, 95% CI -1.40 to 6.01; I²=57%; 4 NRSs; 542 participants; very low CoE) residual renal function. TE may result in little to no difference in short-term residual renal function (MD 1.04, 95% CI 0.25 to 1.83; I²=0%; 2 NRSs; 256 participants; low CoE). We are uncertain about the effects of TE on cancer-specific mortality (risk ratio [RR] 0.90, 95% CI: 0.11 to 7.28; I²=0%; 2 NRSs; 551 participants; very low CoE) and major adverse events (RR 0.48, 95% CI: 0.30 to 0.79; I²=0%; 10 NRS; 2,360 participants; very low CoE).

Conclusions: While TE appears to have similar effects on short term postoperative residual renal function, there were uncertainties on mortality and major adverse events. However, we need rigorous RCTs to elucidate the effects of TE as the evidence stems mostly from NRSs.

Keywords: Nephrectomy; Renal cell carcinoma; Systematic review.

PubMed Disclaimer

Conflict of interest statement

The authors have nothing to disclose.

Figures

Fig. 1
Fig. 1. PRISMA 2009 flow diagram.
Fig. 2
Fig. 2. Risk of bias summary. Review authors’ judgements about each risk of bias item for each included study. Cr, creatinine; GFR, glomerular filtration rate. a:Only abstracts have been published.
Fig. 3
Fig. 3. Risk of bias summary. ROBINS-I outcome set 1: glomerular filtration rate (perioperative), cancer-specific mortality, local recurrence, distant metastasis; set 2: glomerular filtration rate (short-term); set 3: glomerular filtration rate (long-term); set 4: major adverse events; set 5: positive surgical margin; set 6: overall adverse event, hospital stay. Figure created using robvis: https://www.riskofbias.info/welcome/robvis-visualization-tool.

Similar articles

Cited by

References

    1. Bhatt JR, Finelli A. Landmarks in the diagnosis and treatment of renal cell carcinoma. Nat Rev Urol. 2014;11:517–525. - PubMed
    1. Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol. 2015;67:913–924. - PubMed
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7–30. - PubMed
    1. Altekruse SF, Huang L, Cucinelli JE, McNeel TS, Wells KM, Oliver MN. Spatial patterns of localized-stage prostate cancer incidence among white and black men in the southeastern United States, 1999-2001. Cancer Epidemiol Biomarkers Prev. 2010;19:1460–1467. - PMC - PubMed
    1. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med. 2005;353:2477–2490. - PubMed

Grants and funding